Hemab Therapeutics Holdings, Inc. Common Stock

COAG

NASDAQHealthcareBiotechnology

在 GoAI 中打開

前收盤價

US$49.16

+US$0.96 · +1.99%

8月21日下午4:00 ET

盤中時間採用ET。市場資料可能有所延遲。

公司概況

公司網站

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.

產業: Biotechnology
部門: Healthcare
總部: US
執行長: Benny Sorensen
上市以來: 2026年5月1日
僱員: 59

市場位置

日內區間

目前US$49.16，

US$48.76US$49.37

52週區間

目前US$49.16，

US$23.00US$55.42

開盤價: US$48.85
前收盤價: US$48.20
成交量: 39.18萬; 1.07× 平均值
平均成交量: 36.54萬; 日均成交量
市值: 22.96億 USD
貝塔: 1.85; 市場參考 1
50天平均值: US$41.5072; 高於平均水平+18.44%
200天平均值: US$36.221; 高於平均水平+35.72%

財務數據

財務報表

項目（USD）	2025會計年度
研究與開發	5963.2萬 USD
銷售、一般及管理費用	1048.7萬 USD
營業費用	7011.9萬 USD
利息收入	197.4萬 USD
折舊和攤銷	30.4萬 USD
營業利益	−7011.9萬 USD
淨利	−6391.3萬 USD

公司資料更新於 2026年8月24日。

財報歷史與展望

EPS優於預期率: 0%; 優於預期0次、低於預期2次、符合預期0次
平均EPS意外幅度: -6.19%; 2 類似報告
最新每股收益結果: -0.8; 預估-0.73 · 低於預期9.22%

EPS：實際值與預估值

近期已公布業績

實際值預估值

分析師評級

第三方分析師預期可能變動，並非 GoAI 建議。

分析師目標價

平均目標

US$51.40

上漲空間 4.56%

過去 12 個月12個月預測

價格歷史記錄不可用

最高：US$64.00平均的：US$51.40最低：US$36.00

近期分析師行動

3 機構

JefferiesmaintainBuy2026年7月13日

COAG 訊息

defenseworld.net2026年7月19日

Hemab Therapeutics (NASDAQ:COAG) Shares Up 5.5% – Should You Buy?

Hemab Therapeutics Holdings, Inc. (NASDAQ: COAG - Get Free Report)'s share price traded up 5.5% on Friday. The stock traded as high as $47.00 and last traded at $47.00. 17,722 shares traded hands during trading, a…

閱讀原始碼

seekingalpha.com2026年7月15日

Hemab Therapeutics: A Cash-Rich Coagulation Franchise With Multiple Clinical Catalysts

Hemab Therapeutics is building a differentiated coagulation franchise targeting underserved rare bleeding disorders with a prophylactic approach. COAG's robust cash position post-IPO funds operations into 2029,…

閱讀原始碼

globenewswire.com2026年7月14日

Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress

Sutacimig Phase 2 long-term extension (LTE) data show sustained bleed reduction and manageable safety and tolerability; Phase 3 initiation planned 2H 2026

閱讀原始碼

benzinga.com2026年7月13日

Hemab Advances Bleeding Disorder Pipeline

Hemab Therapeutics Inc. (NASDAQ:COAG) on Sunday presented new clinical data for its lead candidate HMB-002 in Von Willebrand disease (VWD) and introduced HMB-003, a new program targeting heavy menstrual bleeding, at the…

閱讀原始碼

globenewswire.com2026年7月12日

Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress

HMB-002 clinical data demonstrate proof of mechanism, with dose-dependent, greater than or equal to 2.4-fold peak increases in Von Willebrand Factor (VWF) and Factor VIII (FVIII), normalization of peak thrombin…

閱讀原始碼

globenewswire.com2026年6月26日

Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress

New results from HMB-002 first-in-human data validate proof of mechanism in Von Willebrand disease (VWD), elevating Von Willebrand Factor (VWF) and Factor VIII (FVIII) levels with subcutaneous dosing; multiple dose…

閱讀原始碼